Mass Tort brief
Litigation Pressure Mounts in Mass Torts
Judges and settlements accelerate timelines across major medical device and pharmaceutical multidistrict litigations.
Mass Tort
Pfizer’s preliminary global settlement resolves thousands of birth control injury claims — proving that robust epidemiological data can force pharmaceutical giants to settle before facing a jury.
BackgroundMultidistrict litigation consolidates similar personal injury lawsuits from across the country under a single federal judge to streamline discovery and pretrial proceedings. Over 5,500 women sued Pfizer, alleging that long-term use of the Depo-Provera hormonal contraceptive shot significantly increased their risk of developing intracranial meningiomas.
- The preliminary agreement renders upcoming representative bellwether trials in Florida unnecessary, allowing lawyers to focus on final terms and individual client distribution frameworks.
- The settlement follows a key Danish epidemiological study that confirmed a strong correlation between progesterone-based birth control methods and brain tumor growth, giving plaintiffs immense leverage.
- Pfizer continues to deny liability and safety defects, but agreed to the settlement framework to eliminate the unpredictable financial risk and public relations fallout of jury trials.
Mass Tort
By seizing control of bellwether case selection, the federal court is overriding corporate delays — pushing cosmetics manufacturers toward early trials that will set the price of a global settlement.
BackgroundBellwether trials are a handful of representative lawsuits selected from a larger pool to test legal theories and gauge jury reactions before a general settlement. The chemical hair relaxer multidistrict litigation is currently the fourth-largest active mass tort in the nation, involving claims of uterine and ovarian cancers.
- Judge Rowland established strict, case-specific expert discovery schedules and ended the practice of letting opposing lawyers trade vetoes on selected cases, stripping both sides of strategic stalling tactics.
- Plaintiffs allege that chemical hair straighteners marketed to Black women contain toxic endocrine-disrupting chemicals, which manufacturers allegedly knew could cause severe hormone-sensitive cancers.
- The restructuring of the case selection process bypasses standard procedural bottlenecks, pushing the massive litigation toward its first trials where jury verdicts will establish baseline settlement values.
Mass Tort
The upcoming federal infant formula trials will test the legal liability of major nutrition manufacturers — deciding if companies are obligated to warn hospitals about biological risks in neonatal wards.
BackgroundThe litigation coordinates hundreds of lawsuits claiming that cow's-milk-based infant formulas cause necrotizing enterocolitis, a life-threatening bowel disease, in premature infants. Abbott Laboratories and Mead Johnson face intense legal pressure from families alleging the companies prioritized profits over neonatal safety.
- More than 810 active cases are now pending in the federal multidistrict litigation, which is set to begin its inaugural test trial, Inman v. Mead Johnson, next month.
- The upcoming federal trials follow a June state appeals court ruling that reversed a $60M verdict against Mead Johnson, contrasted by an April state jury ordering Abbott to pay $70M.
- Plaintiffs argue that manufacturers failed to warn doctors and parents that cow's milk formula significantly increases bowel infection risks compared to donor breast milk, violating safety duties.
Mass Tort
The second Bard PowerPort trial will serve as a crucial test of device design liability — determining whether Becton Dickinson must establish a massive settlement fund to resolve the litigation.
BackgroundImplantable chemotherapy ports are medical devices placed under the skin to deliver medicine directly into a patient's bloodstream. Over 3,000 active lawsuits allege that the Bard PowerPort contains a design defect that makes the catheter prone to cracking, migrating, and causing severe infections.
- The upcoming test trial focuses on claims that defective polymers cause the catheter to fracture, releasing plastic fragments into the bloodstream and causing life-threatening cardiovascular damage.
- Lawyers submitted a joint schedule for the final pretrial conference, indicating that both sides are fully prepared for the high-stakes August courtroom battle in Arizona federal court.
- The outcome of this second trial will heavily influence the settlement value of the remaining thousands of active cases, helping both sides gauge how future juries will treat these claims.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.